Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)

Abbott

Status and phase: Completed; Phase 4

Conditions: Hypertension

Treatments: Drug: Trandolapril

Study type: Interventional

Funder types: Industry

Identifiers

NCT00233532

CANA-03-003

Details and patient eligibility

About

The TRAIL study was conducted to examine the effects of escalating doses of an ACE inhibitor, trandolapril, on lowering blood pressure in Stage 1-2 hypertensive patients.

Enrollment: 2,000 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Stage 1 or 2 Hypertension

Exclusion criteria

• Uncontrolled diabetes
• Subject has a hypersensitivity to ACE inhibitor

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

2,000 participants in 3 patient groups

1

Other group

Treatment:

Drug: Trandolapril

2

Other group

Treatment:

Drug: Trandolapril

3

Other group

Treatment:

Drug: Trandolapril